Swedish registers to examine drug safety and clinical issues in RA

被引：130

作者：

Askling, J

Fored, CM

Geborek, P

Jacobsson, LTH

van Vollenhoven, R

Feltelius, N

Lindblad, S

Klareskog, L

机构：

[1] Karolinska Univ, Dept Med,Karolinska Inst, Clin Epidemiol Unit, Hosp Solna, SE-17176 Stockholm, Sweden

[2] Karolinska Univ, Hosp Solna, Dept Rheumatol, SE-17176 Stockholm, Sweden

[3] Karolinska Inst, SE-17176 Stockholm, Sweden

[4] Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden

[5] Malmo Univ Hosp, Dept Rheumatol, Malmo, Sweden

[6] Lund Univ, S-22100 Malmo, Sweden

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷 / 06期

关键词：

D O I：

10.1136/ard.2005.045872

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Data from several different monitoring systems are examined. The potential for registers based on data obtained from clinical practice, and linkage of such data to national health and population registers, is discussed. The approach described is a possible prototype for long term surveillance systems needed for the safe introduction of new treatments.

引用

收藏

页码：707 / 712

页数：6

相关论文

共 34 条

[1]

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden [J].

Askling, J ;

Fored, CM ;

Brandt, L ;

Baecklund, E ;

Bertilsson, L ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Romanus, V ;

Klareskog, L ;

Feltelius, N .

ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :1986-1992

[2]

Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].

Askling, J ;

Fored, CM ;

Baecklund, E ;

Brandt, L ;

Backlin, C ;

Ekbom, A ;

Sundström, C ;

Bertilsson, L ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Klareskog, L ;

Feltelius, N .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420

[3]

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists [J].

Askling, J ;

Fored, CM ;

Brandt, L ;

Baecklund, E ;

Bertilsson, L ;

Feltelus, N ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Klareskog, L .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1421-1426

[4]

Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study [J].

Baecklund, E ;

Ekbom, A ;

Sparén, P ;

Feltelius, N ;

Klareskog, L .

BRITISH MEDICAL JOURNAL, 1998, 317 (7152) :180-181

[5]

Postmarketing surveillance and adverse drug reactions - Current perspectives and future needs [J].

Brewer, T ;

Colditz, GA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (09) :824-829

[6]

Health care with equity and cost containment [J].

Calltorp, J .

LANCET, 1996, 347 (9001) :587-588

[7]

Central Ethical Review Board, VETT ETH RES INV HUM

[8]

COX-2 inhibitors - A lesson in unexpected problems [J].

Drazen, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1131-1132

[9]

FRIES JF, 1986, WESTERN J MED, V145, P798

[10]

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas [J].

Geborek, P ;

Bladström, A ;

Turesson, C ;

Gulfe, A ;

Petersson, IF ;

Saxne, T ;

Olsson, H ;

Jacobsson, LTH .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (05) :699-703

← 1 2 3 4 →